Enzymaster Completes Acquisition of Sanming Minhe
German biotechnology company Enzymaster has completed the acquisition of Fujian Sanming Minhe Pharmaceutical Technology Co. (Sanming Minhe). Located in China’s Fujian province, 40% of Sanming Minhe’s capacity will be dedicated to manufacturing products using Enzymaster’s processing technology, increasing Enzymaster’s overall production capacity by 50%.
To meet growing demand for enzyme catalysts for cleaner, more efficient process technology solutions, Enzymaster said, it required additional production capacity and, therefore, sought to acquire a strategically located facility utilizing equipment compatible with their Ningbo, China plant. The acquisition of Sanming Minhe met Enzymaster’s criteria given its location in an approved industrial park, proximity to the coast offering ready access to shipping ports, and its new construction.
“We are proud to announce the completion of the Sanming Minhe acquisition,” commented Yong Koy Bong, Enzymaster’s Chairman of the Board of Directors. “With this acquisition, annually, Enzymaster can now produce 600 metric tons of enzymes and compounds utilizing cleaner, greener biomanufacturing processes.”
“The facility has been in operation for less than a year, so the building's design and construction are state-of-the-art,” said Michael Lv, President of Enzymaster. "The added capacity expands our ability to serve our clients worldwide. However, the extremely experienced management team with high levels of expertise was the most attractive to us.”
Daofei Huang was appointed Senior Vice President of Enzymaster and will serve as the Managing Director of Sanming Minhe. Additionally, Zongli Wang, Chufeng Liang, and Xingtao Guo will lead manufacturing, quality assurance and quality control, and pilot scaling and technical transfer, respectively.
